跳至主要内容
临床试验/NCT02539303
NCT02539303撤回1 期

In-vivo Demineralization of Calcific Peripheral Arterial Disease (PAD) Using Local Delivery of Yamani-15/5 Chemical Solution

Mayo Clinic0 个研究点开始时间: 2015年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
撤回
发起方
Mayo Clinic
主要终点
Feasibility

研究概览

简要总结

This is a feasibility pilot study to evaluate the impact of local delivery of Yamani-15/5 (combination of L-Lactic acid 15% and D-Gluconic acid 5%) on vascular calcification of lower extremities in patients with severe peripheral arterial disease (PAD) who were deemed to have unreconstructable arterial disease and who have already been scheduled to undergo limb amputation (below knee or above knee amputation).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Intervention

Experimental

Infusion of Yamani-15/5 chemical solution.

干预措施: Yamani-15/5 chemical solution (Drug)

结局指标

主要结局

Feasibility

时间窗: Change from baseline

Percent of arterial lumen patency measured by angiography and compared to baseline.

次要结局

  • Safety as measured by the number of participants with treatment-related adverse events as assessed by Common Toxicity Criteria for Adverse Effects v4.0.(Compared to baseline)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Houssam Farres, M.D.

Dr. Houssam Farres

Mayo Clinic

相似试验

Delivery of Yamani-15/5 Chemical Solution for PAD | 临床试验